At Keros, our mission is to deliver significant clinical benefit to a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. With a focus on developing differentiated product candidates that are designed to alter TGF-β signaling, we aim to target the pathways critical for the growth, repair and maintenance of blood cells and a number of tissues, including bone, skeletal muscle, adipose and heart tissue. We believe our product candidates have the potential to unlock the full therapeutic benefits of modulating the TGF-β superfamily and provide disease-modifying benefit to patients.

Job Summary:

Keros is searching for a Senior Medical Director to drive clinical development of the lead asset in its clinical pipeline. This Senior Medical Director will be a key medical and scientific leader for rinvatercept development in the neuromuscular therapeutic area, including Duchenne’s muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). The ideal candidate will be a physician with neuromuscular therapeutic area expertise and deep experience in clinical development, regulatory strategy, key opinion leader (KOL) engagement, and trial execution. The Senior Medical Director will primarily function to lead clinical development strategy for rinvatercept, including development of the clinical development plan (CDP), and working within the cross-functional Program Team to ensure effective risk identification and mitigation, and keep planned clinical development activities on track. The Senior Medical Director will also be a key advisor/author for regulatory submissions and will be leading advisory meetings with KOLs and interactions with various health authorities. The role requires medical and scientific oversight of ongoing clinical trials (hands-on participation in aspects of clinical trial execution may be required) to ensure the scientific integrity of the data collected. This is a leadership position best-served by an articulate communicator with a teaching acumen and the gravitas necessary for high-stakes engagements. A genuine interest in learning and understanding the complex science supporting the pipeline is essential. An ability to work collaboratively in a highly matrixed multidisciplinary team setting, and a commitment to developing new treatments for patients in need, are critical for success. This Boston-based role has a flexible hybrid work arrangement requiring 3 days a week in the Lexington, MA office.

Primary Responsibilities

Development Strategy

Lead clinical development strategy for rinvatercept, including development of the CDP and designing future clinical trials, via working within the cross-functional Program Team to ensure strategic alignment.
Contribute to program-level risk identification and mitigation, contributing the clinical development perspective and offering creative solutions to identified problems.
Provide necessary oversight and hands-on execution to ensure rinvatercept clinical development activities are delivered with up-front quality and within planned timelines.
Serve as the key advisor/author for relevant sections of regulatory submissions and associated documents, including queries and requests for information.
Represent Keros in face-to-face and written interactions with various health authorities.
Participate in business development activities when requested by speaking as the rinvatercept clinical development expert an/or by conducting evaluations of in-licensing opportunities aligned with therapeutic area expertise.

Medical and Scientific Oversight for Clinical Trials

Provide medical leadership and expertise to cross-functional study teams, guiding the aligned execution of rinvatercept clinical trials in accordance with strategic goals.
Communicate trial progress, risks, and emerging data insights to internal teams and senior leadership, as appropriate.
Lead or supervise trial-related committees such as a Safety Review Committee, Data Safety Monitoring Board, Steering Committee, etc. when appropriate for the trial design.